Literature DB >> 24061003

Analysis of protein composition and protein expression in the tear fluid of patients with congenital aniridia.

Robert Ihnatko1, Ulla Edén, Neil Lagali, Anette Dellby, Per Fagerholm.   

Abstract

Aniridia is a rare congenital genetic disorder caused by haploinsuffiency of the PAX6 gene, the master gene for development of the eye. The expression of tear proteins in aniridia is unknown. To screen for proteins involved in the aniridia pathophysiology, the tear fluid of patients with diagnosed congenital aniridia was examined using two-dimensional electrophoresis (2-DE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Two-dimensional map of tear proteins in aniridia has been established and 7 proteins were differentially expressed with P<0.01 between aniridia patients and control subjects. Five of them were more abundant in healthy subjects, particularly α-enolase, peroxiredoxin 6, cystatin S, gelsolin, apolipoprotein A-1 and two other proteins, zinc-α2-glycoprotein and lactoferrin were more expressed in the tears of aniridia patients. Moreover, immunoblot analysis revealed elevated levels of vascular endothelial growth factor (VEGF) in aniridia tears which is in concordance with clinical finding of pathological blood and lymph vessels in the central and peripheral cornea of aniridia patients. The proteins with different expression in patients' tears may be new candidate molecules involved in the pathophysiology of aniridia and thus may be helpful for development of novel treatment strategies for the symptomatic therapy of this vision threatening condition. BIOLOGICAL SIGNIFICANCE: This study is first to demonstrate protein composition and protein expression in aniridic tears and identifies proteins with different abundance in tear fluid from patients with congenital aniridia vs. healthy tears.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aniridia; Keratopathy; LC–MS/MS; Tear fluid; Two-dimensional electrophoresis; α-Enolase

Mesh:

Substances:

Year:  2013        PMID: 24061003     DOI: 10.1016/j.jprot.2013.09.003

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  4 in total

1.  Topical bevacizumab treatment in aniridia.

Authors:  Ruth Lapid-Gortzak; Nathalie T Y Santana; Carla P Nieuwendaal; Maarten P Mourits; Ivanka J E van der Meulen
Journal:  Int Ophthalmol       Date:  2017-06-15       Impact factor: 2.031

Review 2.  The diagnosis of limbal stem cell deficiency.

Authors:  Qihua Le; Jianjiang Xu; Sophie X Deng
Journal:  Ocul Surf       Date:  2017-11-04       Impact factor: 5.033

Review 3.  Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine.

Authors:  Suzanne Hagan; Eilidh Martin; Amalia Enríquez-de-Salamanca
Journal:  EPMA J       Date:  2016-07-13       Impact factor: 6.543

Review 4.  Fluorescence Sensing Technologies for Ophthalmic Diagnosis.

Authors:  Yuqi Shi; Yubing Hu; Nan Jiang; Ali K Yetisen
Journal:  ACS Sens       Date:  2022-05-31       Impact factor: 9.618

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.